Findings

What do systematic reviews say?

13 questions · 15 findings · 2 reviews · Airways · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 13.3%GRADE not reported 0 · 0%Very low 4 · 26.7%Low 8 · 53.3%Moderate 1 · 6.7%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- ICS dose reduction vs no change · Asthma control (short asthma morbidity score)
  Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 242 participants
  Low
Direct match · question page
- ICS dose reduction vs no change · Asthma control assessed by: Asthma Symptom Scale from: 0 (no symptoms) to 5 (severe symptoms)
  Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 150 participants
  Low
Direct match · question page
- ICS dose reduction vs no change · Lung function, FEV1 (L) assessed by: spirometry
  Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 261 participants
  Low
Direct match · question page
- ICS dose reduction vs no change · Lung function, reduction in FEV1 (% predicted, change from baseline)
  Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 14 participants
  Very low
Direct match · question page
- ICS dose reduction vs no change · Exacerbation requiring OCS
  Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  OR 1.86 [0.16, 21.09]
  2 studies · 261 participants
  Very low

ICS dose reduction vs no change

FEV1 · adults with asthma

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

ICS dose reduction vs no change

Rate of exacerbations requiring systemic corticosteroids · adults with asthma

It is very uncertain whether ICS dose reduction changes exacerbation requiring OCS compared with no change (very low certainty).

2 findings from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
OR 1.86 [0.16, 21.09]
2 studies · 261 participants
Very low
Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
OR 1.31 [0.82, 2.08]
2 studies · 569 participants
Low

ICS dose reduction vs no change

SAEs · adults with asthma

ICS dose reduction showed no clear difference in all‐cause SAEs compared with no change (low certainty).

2 findings from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
OR 0.6 [0.11, 3.33]
2 studies · 569 participants
Low
Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
OR 1.24 [0.25, 6.25]
2 studies · 742 participants
Low

ICS dose reduction vs no change

Steroid‐related AEs ‐ not reported · adults with asthma

The review found no eligible studies for this question.

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ICS dose reduction vs no change

St. George's Respiratory Scale score (change from baseline) · adults with asthma

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 229 participants
Low

ICS dose reduction vs no change

Severe exacerbations requiring hospitalisation over the study period · adults with asthma

ICS dose reduction showed no clear difference in exacerbation requiring hospitalisation compared with no change (low certainty).

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
OR 4.06 [0.45, 36.86]
2 studies · 569 participants
Low

ICS dose reduction vs no change

Asthma control · adults with asthma

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Low

ICS dose reduction vs no change

Steroid‐related AEs · adults with asthma

It is very uncertain whether ICS dose reduction changes steroid‐related AEs compared with no change (very low certainty).

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
OR 0.76 [0.16, 3.54]
2 studies · 261 participants
Very low

ICS dose reduction vs no change

Change in AQLQ · adults with asthma

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 554 participants
Very low

ICS dose reduction vs no change

FEV1 (L) · adults with asthma

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 261 participants
Low

ICS dose reduction vs no change

Exacerbation: hospital 17 weeks · adults with asthma

The review found no eligible studies for this question.

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ICS dose reduction vs no change

Asthma control (short asthma morbidity score) · adults with asthma

1 finding from 1 review

Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 242 participants
Low

Intervention not reported

% change from baseline ICS dose Duration of trials: 12 to 24 weeks More reduction is better · adults and adolescents with persistent asthma

1 finding from 1 review

Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 930 participants
Moderate